Artiva Biotherapeutics, Inc. financial data

Symbol
ARTV on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5505 Morehouse Drive, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -1.2K % -6692%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.4M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 18.9M shares +2242%
Weighted Average Number of Shares Outstanding, Diluted 18.9M shares +171%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.5M USD +3.51%
General and Administrative Expense 4.81M USD +73.1%
Operating Income (Loss) -18.3M USD -270%
Nonoperating Income (Expense) 863K USD +84.4%
Net Income (Loss) Attributable to Parent -65.4M USD -128%
Earnings Per Share, Basic -0.92 USD/shares -107%
Earnings Per Share, Diluted -0.92 USD/shares -157%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.2M USD -24.8%
Cash, Cash Equivalents, and Short-term Investments 185M USD
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 189M USD +136%
Property, Plant and Equipment, Net 6.37M USD -21.3%
Operating Lease, Right-of-Use Asset 13.8M USD -16.6%
Other Assets, Noncurrent 267K USD -31.9%
Assets 210M USD +99.4%
Accounts Payable, Current 1.12M USD +82.6%
Employee-related Liabilities, Current 4.83M USD +19.4%
Accrued Liabilities, Current 7.39M USD -7.8%
Liabilities, Current 12.3M USD +0.21%
Operating Lease, Liability, Noncurrent 10.6M USD -20.6%
Other Liabilities, Noncurrent 73K USD 0%
Liabilities 22.9M USD -54.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -129K USD -142%
Retained Earnings (Accumulated Deficit) -247M USD -36.1%
Stockholders' Equity Attributable to Parent 187M USD
Liabilities and Equity 210M USD +99.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 424K shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40.5M USD -24.7%
Deferred Tax Assets, Valuation Allowance 63.1M USD +43.1%
Deferred Tax Assets, Gross 68.2M USD +35.3%
Operating Lease, Liability 14.2M USD
Depreciation 600K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.3M USD -251%
Lessee, Operating Lease, Liability, to be Paid 17M USD
Property, Plant and Equipment, Gross 12.3M USD +5.72%
Operating Lease, Liability, Current 3.62M USD +0.61%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.53M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.07M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.85M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.52M USD
Deferred Tax Assets, Operating Loss Carryforwards 29.7M USD +45.4%
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 5M USD +24.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.63M USD
Deferred Tax Assets, Net of Valuation Allowance 5.07M USD -19.1%
Share-based Payment Arrangement, Expense 1.91M USD +39.1%